News more

  • In Memoriam: Richard A. Wiley  [Read More]
  • Foley Hoag Client inStream Media Receives Funding  [Read More]
  • Chambers 2009 Ranks Foley Hoag in 13 Leading Practice Areas  [Read More]
  • Foley Hoag's M&A, Venture Capital and Antitrust Practices Honored by the Legal 500 2009 U.S. Guide  [Read More]
  • Victim Rights Law Center Recognizes Foley Hoag's Pro Bono Program at Annual Shining Star Awards  [Read More]

Publications more

  • EEC Perspectives - May 2009 [Read More]
  • National Cap-and-Trade Legislation Passes the House: At 1,428 Pages, Nearly Something for Everyone [Read More]
  • U.S. Supreme Court Holds That City Discriminated Against White Firefighters [Read More]
  • The Alphabet Soup of the Financial System Bailout [Read More]
  • Trade Secrets: A Guidebook for Technical and Business Professionals Involved in Legally Protecting Products, Technologies and Services [Read More]
  • Medicare Authorities To Reduce Payment for Covered Items or Services [Read More]

Events more

July 7, 2009 Financial Industry Regulatory Authority: Hedge Funds [Read More] FINRA International
London
July 15, 2009 Think Global-Act Local: Transatlantic Perspectives for Climate Protection at the City Level [Read More] Foley Hoag LLP (Boston Office)
Boston, MA
September 30, 2009 ACI's Advanced Forum on Biotech Patents [Read More] Royal Sonesta Hotel
Boston, MA

Client Successes

  • Biomedical Advanced Research and Development Authority (BARDA)
    In a move that created enormous opportunities for early-stage life sciences companies, last year the U.S. Congress revitalized the federal government’s program supporting the development of medical countermeasures critical to protecting the nation against bioterrorism and pandemic threats. The resulting legislation created an agency within the Department of Health and Human Services (HHS), the Biomedical Advanced Research and Development Authority (BARDA). BARDA will inject more than $1 billion into research, development, and procurement of vaccines, antivirals and diagnostics. BARDA enhances coordination between government and emerging companies through support of advanced research and development, the vital phase that occurs in between basic research and commercialization. On behalf of the venture capital firm, Kleiner Perkins Caulfield & Byers, Foley Hoag worked with the HHS, Congressional members, and staff to craft legislation strengthening the nation’s response to pandemic outbreaks and bioterrorism. The key financing aspect of the legislation provides much-needed funding to allow early stage companies to traverse the “valley of death” before product commercialization. The legislation authorizes the Secretary of HHS to expedite contracts and grants, and the Director of BARDA to identify areas of unmet need, spurring further innovation and investment. BARDA institutionalizes the important partnership between the federal government and the life sciences industry, critical to safety, innovation and economic vitality. [Read More]
  • HyperBranch Medical Technology, Inc.
    For our client HyperBranch Medical Technology, Inc., a leader in the field of polymeric medical sealants, we assisted with the intellectual property portfolio strategy in connection with obtaining CE Mark designation for the company’s OcuSeal product. OcuSeal is a liquid ocular bandage used to stabilize ocular wounds following surgical or non-surgical trauma. CE Marking denotes that a product complies with all requirements of European health, safety, and environmental product legislation, and is an important step in bringing products to market overseas. HyperBranch began its research in 2004 with the objective to develop strong enough polymer sealants to ultimately replace sutures that would be easy to use, and would not interfere with natural healing. The Durham, North Carolina medical device company has also, been developing advanced surgical sealants for dura (brain), pleural (lung) and hernia mesh fixation. These products are all at various stages of clinical and pre-clinical development. Read more about HyperBranch Medical Technology here. [Read More]